Journal of Advanced Zoology
ISSN: 0253-7214
Volume 45 Issue 2 Year 2024 Page 523-532

Role Of Biomarkers In Enhancing Accuracy Of Human Disease Diagnosis

Dr A. Lazha[1*], Dr Konkala Anand[2], Dr Inamul Hasan Madar[3], Dr E. Nandhine MD (S)[4], Dr P. Chakravarthi MD (S)[5], Dhiramani Bhuyan[6]

[1]Professor Sri Sairam Siddha Medical College and Research Centre, Chennai.*
Email: lazhadinesh@gmail.com
[2]Assistant professor of zoology Govt City College Osmania University Hyderabad.
Email: konkala27@gmail.com
[3]Associate Professor, Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha University, Chennai. oncoinam@gmail.com
[4]Lecturer Sri Sairam Siddha Medical College and Research Centre Chennai.
Email: nandhini@sairamsiddha.edu.in
[5]Lecturer Sri Sairam Siddha Medical College and Research Centre Chennai.
Email: chakravarthi@sairamsiddha.edu.in
[6]Department of Zoology Jagannath Barooah College (Autonomous) Jorhat, Assam
Email: dhiramanibhuyan@gmail.com

***Corresponding Author:** Dr A. Lazha*
**Professor Sri Sairam Siddha Medical College and Research Centre, Chennai.*
Email: lazhadinesh@gmail.com

Abstract

In modern medicine, the role that biomarkers play in improving the precision of human illness diagnosis has grown crucial. Biomarkers are measurable indicators of natural cycles or circumstances that provide valuable insights into the early identification, prediction, and response to therapy of many diseases. The significance of biomarkers in improving the accuracy of symptoms by elucidating their ability to represent cellular and subatomic changes associated with specific illnesses. Their potential in the screening, diagnosis, and observation of diseases such as neurological problems, cardiovascular ailments, and malignant growths has been unparalleled. The coordination of state-of-the-art revelations like proteomics, metabolomics, and genomes consider an intensive assessment of biomarkers, empowering medical experts to tweak meds in light of the novel qualities of every patient. In the appraisal of disease risk, the utilization of biomarkers as early advance notice systems has filled fundamentally in the new past. Biomarkers are signs of disease cycles, regular normal cycles, or pharmacological responses to treatment. Society is enormously affected by the utilization and irrefutable proof of biomarkers in the clinical and medical areas. We take a gander at the scope of encounters, different definitions, portrayals, qualities, and exposures of biomarkers in this review. Moreover, an evaluation is made on the likely uses of biomarkers all through the past 10 years in the recognizable proof, representation, and the board of different sicknesses.

Keywords: Biomarkers, Enhancing Accuracy, Human Disease Diagnosis, Cardiovascular Disorders, Neurodegenerative Conditions

1. INTRODUCTION

Since biomarkers assume a basic part in working on the accuracy of human disease detection, the field of medical diagnostics has encountered wonderful development. Biomarkers are quantifiable signs of nuclear components or regular cycles that can be recognized in different natural fluids or tissues. These nuclear markings give essential data about an individual's physiological and psychotic conditions, considering more exact and opportune disease distinguishing proof. The utilization of biomarkers has overturned the scientific landscape by giving proficient and effortless methods to distinguishing and observing diseases. As well as giving understanding into the different utilizations of biomarkers and their effect on dealing with quiet results, this meeting investigates the significance of biomarkers in supporting the accuracy of human disease diagnosis.

Biomarkers act as fundamental devices in the field of diagnosing human diseases, giving a subatomic focal point through which to see the marvelous operations of the human body. These biomarkers may be anything from proteins and nucleic acids to metabolites and cell structures, and every one gives one of a kind data about an individual's condition of wellbeing or the presence of essential diseases. The capacity to recognize and survey these biomarkers empowers medical experts to pursue more educated and pragmatic choices, elevating a proactive way to deal with medical services. This progress from customary secondary effect based diagnosis to subatomic level evaluations furnishes doctors with a complete understanding of diseases, permitting them to work with early mediation and individualized treatment plans.

One of the main benefits of biomarkers is their effortlessness with regards to test assortment from promptly accessible regular fluids like blood, pee, or spit. This differentiations with standard insightful methodologies, which here and there need intrusive methods or wide imaging. Medical specialist organizations can ease patient inconvenience and lessen the gamble of entanglements related with intrusive methodology by controlling biomarkers. Biomarker-based diagnostics are broadly acknowledged because of their convenience and flexibility, which works on their accessibility and sensibility in medical administrations systems across the globe.

Past just distinguishing diseases, biomarkers assume a basic part in checking the movement of diseases, assessing the viability of medicines, and projecting patient results. Unequivocal biomarkers, for example, can assist with deciding treatment choices, give bits of knowledge into the forcefulness of growths, and survey the reaction to those medicines in oncology. Biomarkers help in checking glucose levels and altering therapy plans in constant diseases like diabetes. This dynamic, progressing perception, alongside biomarkers, works on expressive accuracy and extends the length of customized treatment, properly tending to every patient's uncommon normal beauty care products.

Biomarkers tackle a ground-breaking part of medical services by fundamentally working on the accuracy of diagnosing human diseases. Their flexibility, security, and capacity to give inconspicuous bits of knowledge into organic cycles make them crucial instruments for the two subject matter experts and doctors. The job of biomarkers in medical services is prepared to develop as headways in advancement and discovery keep on unwinding the intricacy of subatomic markings, forming a future where determinations are precise, fruitful, and more tweaked.

2. LITERATURE REVIEW

Amin (2021) digs profoundly into the meaning of polyamine biomarkers as markers for different human diseases. Putrescine, spermidine, and spermine are instances of polyamines that assume fundamental parts in the division, development, and duplication of cells. The designers feature their veritable potential as biomarkers because of their part in major cellular capabilities. The review features the worth of dysregulated polyamine processing as far as both forecast and side effects by analyzing its relationship with the improvement of diseases. The review underscores the requirement for careful examination to explain the explicitness and information on polyamine biomarkers in a scope of sicknesses. Moreover, Amin et al. examine the difficulties related with creating reference runs and standardized measures for polyamine levels, which is a urgent step towards integrating a translation of their genuine limit into clinical practice. The creators additionally present the clever idea of polyamine absorption, which elevates long haul studies to explain the worldwide adjustments in polyamine profiles related with the movement of disease.

Carlos and Josephs (2023) make an important commitment to the developing field of clinical assessment during the biomarker time. The review tends to the exceptional relationship that exists between arising biomarkers and conventional clinical evaluations with regards to disease diagnosis and the board. That's what the creators contend

despite the fact that biomarkers give important experiences, they ought to supplement instead of supplant conventional clinical decisions. The review investigates the commonly valuable connection between biomarker data and clinical mastery, featuring the significance of a complete and coordinated approach. The review reveals insight into the difficulties related with incorporating biomarkers into clinical practice, including standardization, approval, and the foundation of standards in light of proof. To defeat any snags between the discovery of biomarkers and the execution of clinical preliminaries, Carlos and Josephs underline the significance of interdisciplinary cooperation between specialists, trained professionals, and industry accomplices. They likewise examine the moral ramifications of utilizing biomarkers, stressing the requirement for open correspondence with patients in regards to the impediments and weaknesses related with these scientific apparatuses.

The American Heart Affiliation gives an exhaustive and levelheaded depiction of the job of biomarkers in the counteraction, diagnosis, and treatment of cardiovascular breakdown in Chow et al. (2017). The review coordinates proof on biomarkers, for example, troponins, B-type natriuretic peptide (BNP), and others, in the diagnosis of cardiovascular breakdown, risk evaluation, and remedy of restorative measures. The creators stress that to work on understanding thought, biomarker data ought to be composed into clinical unique cycles. The examination features the job that cardiovascular breakdown biomarkers play in early diagnosis and forecast by outlining the field's progressions around here. As indicated by Chow et al., biomarkers can be utilized to foresee results, survey treatment reaction, and fit supportive strategies. The survey likewise talks about difficulties, for example, cost-ampleness and receptiveness, in involving biomarker-coordinated procedures in clinical practice. The creators ask more exploration to improve and expand the utilization of biomarkers in cardiovascular disease the executives, featuring the requirement for expanding cooperation among researchers and medical experts.

Condrat et al. (2020) give an exhaustive outline of the latest discoveries about the job of microRNAs (miRNAs) as biomarkers in different diseases, with an emphasis on their part in diagnosis and expectation. The study features the job that miRNAs play in quality explanation as well as their regulatory job in significant cell exercises. Since miRNAs are steady in natural fluids, the creators research their true capacity as effortless biomarkers, with an emphasis on their expected application in liquid biopsy. The review dives into explicit instances of miRNAs ensnared in various sicknesses and their expressive and prescient importance. Condrat et al. investigate the difficulties of standardizing miRNA ID methods and laying out broadly acknowledged reference ranges. Moreover, the study checks out at the arising job of miRNAs in customized medication, featuring their genuine capacity to direct designated medicines. To approve and work on the convenience of miRNAs as biomarkers and plan for their reconciliation into standard clinical practice, the creators advocate for additional examination.

Dulewicz et al. (2022) center around cerebrospinal liquid (CSF) biomarkers to additional the field of Alzheimer's disease (Advancement) diagnosis. The overview tracks the making of scientific devices for advancement and the fundamental job that CSF biomarkers play in empowering exact and early diagnosis. The creators talk about clear biomarkers, for example, phosphorylated tau, outright tau, and amyloid-beta 42, underlining their worth in addressing fundamental masochist cycles related with advancement. Basically, the paper assesses the present status of CSF biomarkers in clinical practice, featuring their benefits and impediments. The difficulties of standardization, unpredictability, and receptiveness related with CSF biomarker testing are examined by Dulewicz et al. The overview features the capability of CSF biomarkers to screen the movement of disease and survey reaction to treatment. The creators advocate for progressing examination to further develop side effects calculations and show the clinical convenience of CSF biomarkers in standard Advancement diagnosis.

A broad assessment into the human microbiome's true capacity as a focal point for distinguishing biomarkers reminiscent of disease is introduced by Hajjo et al. (2022). The review underscores the perplexing relationship that exists between human government assistance and the microbiome, featuring the job that microbial organizations play in different physiological cycles and disease states. The creators go into late improvements in microbiome research, offering knowledge into how changes in the microbiome's structure and capability can act as signs of normal ailments. The review talks about the methodologies taken to zero in on the human microbiome, going from metagenomic examinations to high-throughput sequencing strategies. Hajjo et al. present explicit cases, including as gastrointestinal issues, metabolic diseases, and safe related sicknesses, in which the microbiota has exhibited suggestive potential. The creators underscore that to manage the translation of discoveries into clinically usable decisive biomarkers, microbiome examination should stick to standardized conventions, reference data sets, and reproducibility.

3. BIOMARKERS IN EARLY DISEASE DETECTION

Biomarkers play a crucial role in the early diagnosis of illnesses, providing a vital way to identify subtle physiological changes associated with various medical conditions. Early disease detection is essential to medical care since it allows for more advanced therapy outcomes and convenient intervention. Subatomic, biochemical, or cell pointers are examples of biomarkers; they are measurable indicators of normal or anomalous natural cycles. Biomarkers are considered early warning indicators of disease that occur prior to the onset of clinical adverse effects. These indicators can be differentiated using many ways of demonstration, such as subatomic examinations, imaging techniques, or blood testing. For example, elevated blood levels of particular proteins, clear genetic alterations, or odd imaging examples may function as biomarkers indicative of an underlying disease even prior to noticeable side effects occurring.

In situations such as malignant development, when early disease discovery significantly improves the chances of successful treatment, the use of biomarkers in early disease detection is particularly evident. Using biomarkers, medical professionals can identify potentially dangerous cells or specific subatomic alterations that could indicate the development of cancer. This early distinguishing evidence considers more focused and unobtrusive intercessions, leading to superior silent outcomes and potentially lessening the overall weight of therapy.

Additionally, biomarkers enhance the assessment of treatment plans for illnesses with known genetic predispositions or inherent risk factors. Medical care providers can reduce the risk of disease progression by implementing preventative measures, initiating routine monitoring, or providing tailored interventions by identifying individuals at high risk through biomarker analysis.

Nevertheless, there are obstacles in the way of the identification and validation of reliable biomarkers for the early diagnosis of illness. To ensure accurate results, a comprehensive survey of the particularity and responsiveness of biomarkers should be conducted. Additionally, a broad and widespread clinical reception depends on the establishment of standardised norms for biomarker testing and interpretation.
Biomarkers' role in early disease identification is essential to the advancement of medical care practices. These subatomic cues provide a window of opportunity for pre-emptive intervention, laying the groundwork for precisely tailored medicine delivery. The potential for disrupting early identification of a variety of diseases, working towards quiet outcomes, and reducing the cultural and financial burden of medical care exists as biomarker discovery research advances.

4. CLASSIFICATION OF BIOMARKERS

Biomarkers have been sorted by various standards, like their qualities, clinical purposes, and, at long last, genetic and molecular biology strategies (Figure 1).



Figure 1: Diagrammatic representation of the biomarker classification.

4.1. Genetic and molecular biology methods

The genetic and molecular biology approach shows that biomarkers are isolated into three classifications: Types 0, 1, and 2. Type 0 is an unmistakable verifiable biomarker that is corresponded with long haul clinical results and can be assessed in stage 0 clinical investigations of a disease. Type 1 medication activity biomarkers show a medication's mediations, valuable impacts, component of activity, and toxicological impacts. Type 2 biomarkers are viewed as a stand-in for clinical result evaluations of sickness and help in expecting reactions to supportive mediations.

4.2. Characteristics

In view of their attributes, biomarkers can be arranged into three principal classifications: molecular, cell, and imaging biomarkers.

4.2.1. Molecular biomarkers

Molecular biomarkers are markers that are determined utilizing genomic and proteomic procedures. They assume a vital part in the diagnosis of sicknesses and have applications in the logical examination of disease transmission, randomized clinical fundamental preliminaries, disease counteraction, leader diagnosis, and mystery. Biophysical attributes permit these markers to be estimated in regular examples like blood, plasma, bronchoalveolar lavage liquids, cerebrospinal liquid, and biopsies. They contain a huge swath of parts, going in size from little to gigantic, including particles, proteins, lipids, metabolites, nucleic acids (DNA and RNA), and peptides. Three kinds of molecular biomarkers are recognized: qualities, proteins, and engineered synthetic substances.

4.2.1.1. Chemical biomarkers

Substance biomarkers store data about inborn blunders coming about because of gastrointestinal lot or inherited conditions of cancers, handicaps, and metabolic diseases; they likewise store data about the disease's irreversible movement, food admission, medication, compound, and defilement receptiveness. By and large, 1089 manufactured biomarkers in the online molecular biomarkers data set (MarkerDB) were related with 448 conditions/diseases and 106 opening. It is feasible to unequivocally and quantitatively resolve a few compound biomarkers with high accuracy and steady quality. Figure 2 shows a couple of instances of these biomarkers.



Figure 2: A few illustrations of chemical biomarkers.

4.2.1.2. Protein biomarkers

For the purpose of identifying various natural changes, the protein biomarkers are useful. They can be used as indicators of the progression of inflammation, stress, and vulnerability, as well as associated illnesses like cancer, diabetes, heart disease, neurological disorders, and other ailments. More than 160 diseases are covered by 142 protein biomarkers in the MarkerDB database. Figure 3 shows the names of the two types of these biomarkers together with their corresponding protein structures.



Figure 3: Two types of protein biomarkers.

4.2.1.3. Genetic biomarkers

Throughout the span of the most recent quite a while, the genetic (DNA change, DNA single nucleotide polymorphism, and karyotypic) types have been broadly utilized as biomarkers for distinguishing sicknesses. There are 154 karyotype biomarkers and 26374 genetic biomarkers in the Marker DB data assortment. The main biomarkers related with in excess of 319 diseases or disorders are DNA markers. Since most ailment cells gather actual alterations, genetic biomarkers are not completely gotten comfortable that mood of all nucleated cells withdrew from any natural model, particularly in harmful improvement malignancies.

4.2.2. Cellular biomarkers

Clinical and laboratory studies can make use of cellular biomarkers, which are naturally occurring and quantitative markers. Cellular biomarkers are frequently measured and evaluated in bodily fluids such as blood or fragile tissue in order to visualize them or determine their propensity to respond to a specific treatment. These biomarkers consider how cells are categorized, arranged, measured, and depicted based on their appearance and physiological characteristics.

4.2.3. Imaging biomarkers

Since they are effectively available, financially practical, and safe, imaging biomarkers might be the most frequently used system in clinical settings. Contrasting early sickness diagnosis with molecular biomarkers uncovers a clinical benefit. A brand name that is impartially assessed and determined as a sign of normal pathogenic cycles, regular cycles, or pharmacologic reactions to a valuable intervention is known as an imaging biomarker. There are three classifications of imaging biomarkers: magnetic resonance imaging (X-beam), computed tomography (CT), and positron emission tomography (PET). PET, which tracks and measures how much glucose consumed by body cells, can be utilized to evaluate the capability of disease medicines. CT is an exhibition strategy that gets cross-sectional and three-dimensional (3D) images of the human body by utilizing ionizing radiation to screen development status. X-beam strategy with extremely high spatial objective images is generally ordinarily utilized to fathom development ailments, both threatening and neurodegenerative. The high spatial goal, delicate tissue contrast, capacity to overview physiology (e.g., oxygenation, dispersal, and vascularization), and capacity to get a few distinctions in a solitary assessment are a couple of the many advantages of X-beam innovation. Certain X-beam biomarkers have either been laid out or are currently being laid out for clinical application in oncological assessments. For the diagnosis of prostate, chest, and hepatocellular diseases, separately, these incorporate Prostate Imaging Reporting and Data System (PI-RADS), Chest Imaging Reporting and Data System, and Liver Imaging Reporting and Data System. It is pivotal to take note of that few methods, like endoscopic, X-beam, mammography, ultrasound, optical coherence tomography, and close to infrared

spectroscopy, have additionally been utilized as imaging biomarkers to get data for the diagnosis of different diseases. Figure 4 shows a couple of models from the imaging biomarkers assortment.



Figure 4: Instances of biomarkers for imaging.

4.3. Clinical applications

Biomarkers are categorized into three groups based on the clinical stages in which they are used: therapeutic, prognostic, and diagnostic.

4.3.1. Diagnostic biomarkers

These biomarkers are utilized to affirm the presence of specific diseases. For example, liver-type fatty acid-binding protein (L-FABP) is a diagnostic biomarker for deciding the seriousness of renal injury or oxidative strain, cardiovascular troponin is utilized to analyze cardiovascular muscle injury, scatterings of 3-hydroxy-fatty acids are utilized for planctomycetes, a bunch of glycans is utilized as a harmful development biomarker, glutamate is utilized for natural weight and changed processing, cate statin is utilized to decide the psychological tension response related with expanded mortality among heart patients, and glutamate is utilized to decide instinctual weight and altered absorption.

4.3.2. Prognostic biomarkers

Prognostic biomarkers give data about the condition of a disease by screening, assessing, and working out an increment or diminishing in the interior forerunners that the disease might cause. For instance, prognostic biomarkers for cardiovascular sicknesses incorporate circulatory strain and cholesterol; renal impedance and cardiovascular breakdown incorporate N-acetyl-beta-d-glucosaminidase; catalyst reactivity to ketamine incorporates d-serine; and bone and skeletal metastases incorporates osteocalcin.

4.3.3. Therapeutic biomarkers

These biomarkers assume an essential part in observing the clinical reaction and the impact of treatment on sickness or tension, and they are powerful in the therapy of disease. Proteins, for example, exosomes and miRNAs are instances of therapeutic biomarkers that might be utilized in specific medicines. Takamura et al. utilized malondialdehyde-changed low-thickness lipoprotein as a decent indicator of clinical results in patients with periphery hall disease following endovascular treatment. Clinical preliminaries on d-serine uncovered that it is a practical treatment biomarker for individuals experiencing schizophrenia and sorrow. As a serum development marker, CA15-3 is helpful for checking the course of treatment for chest disease. Glycosylated hemoglobin A1c, or HbA1c, was utilized to screen the advancement of against diabetic medicine.

5.BIOMARKER DISCOVERY

Throughout the course of recent years, there have been critical progressions in science and actual science, prompting upgrades in the diagnosis and appraisal of disease. These progressions have prompted the recognizable proof of novel and imaginative disease markers in conditions including the safe system, malignant growth, endocrine systems, genetics, actual injury, gastrointestinal issues, and different conditions. More often than not,

these headways have prompted the distinguishing proof of biomarkers that have been clarified by regular or routine methods like immunoassays, histology, or clinical normal science. Finding a little gathering of qualities that can be utilized to effectively and monetarily request one more model and carry out it into clinical practice is the essential inspiration driving the production of biomarkers. Throughout recent years, critical headway has been made in the ID of biomarkers. Chemometrics and systems biology strategies can be applied to the turn of events and ID of biomarkers. The key limits in biomarker discovery audit are survey setup, test grouping system, test assessing, data assessment, and perception. Two essential types of procedures have been utilized for biomarker recognizable proof from biofluid sources like blood, pee, milk, and cell culture media: centered and untargeted. The picked system considers getting an exhaustive understanding of the physiology/pathology and disease processes as well as the distinguishing proof of novel biomarkers that might be delivered or provided throughout the disease and that can be evaluated utilizing obvious procedures. A fair-minded strategy for biomarker ID that simply relies upon an assortment of "omics" profiling procedures utilized for purposefully dissecting organic liquids is known as an untargeted approach. Genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, and secretomics stages can be generally used to recognize molecular biomarkers. Figure 5 presents a portion of these "omics" forward leaps.



Figure 5: The "omics" technology taxonomy.

5.1. Genomics

A genome is a deliberate investigation of the construction, capability, and articulation of each and every nucleotide succession in a living life form. A high throughput breakthrough called genomics is used to define genetic signals and the ensuing protein designs and successions. A cell's or organism's whole DNA, including its sequences, variations, and comments, is called its genome.

5.2. Proteomics

Originally intended to refer to the protein complement of the genome; the term proteome is now used to refer to the vast field of study encompassing proteins and peptides. The organization of proteins that the genome encodes at a given point in time is known as the proteome. The proteome, which varies in response to the patient's physiological state and ecological factors, is a complex and dynamic representation of the two attributes as well as the climate. The proteomics approach and innovation is the field that focuses on these sets. Proteomics is the study and unique evidence of the more than a million high-quality components that finish the natural cycles in the human body. For proteomics tests, mass spectrometry and fluid chromatography are the informative phases.

5.3. Transcriptomics

The transcriptome is an immense preliminary instrument for breaking down top notch verbalization. Due to different redesigns like pH, light, temperature, and regular energizers, transcriptomics empowers the ID and appraisal of the general plan of all RNA species, including messenger RNAs, non-coding RNAs, and little RNAs (microRNA, minimal intruding RNA, piwi-coordinating RNA, and minimal interfering RNA). The transcriptome investigation exhibits how different eating regimen plans, augmentations, and parts of food sources influence the outflow of explicit qualities.

5.4. Metabolomics

As a rule, "metabolomics" alludes to the worldwide examination of all metabolites inside a characteristic system (cell, tissue, or living creature) comparable to medications or sicknesses. There are low molecular weight atoms in the metabolome. These blends straightforwardly change the phenotypic of the cell because of enzymatic responses and quality records. Estimating metabolites is a typical use of metabolomics. Lipids, amino acids, peptides, regular acids, and nucleic acids are instances of metabolites. These substances are found in human fluids and emissions like blood, spit, pee, and cerebrospinal liquid. Infrared spectroscopy, nuclear magnetic resonance, predominant execution liquid chromatography, liquid chromatography-mass spectrometry, and gas chromatography-mass spectrometry can be generally used to examine the metabolomics biomarkers.

6. CONCLUSION

Biomarkers play a critical part to play in working on the accuracy with which human diseases are analyzed, and this has molded the quickly developing field of medical diagnostics. The complete understanding of molecular and cellular changes related with numerous diseases, worked with by biomarker research, has introduced another period of accuracy medication. Consolidating cutting edge advances has empowered the ID and approval of various biomarkers and set them up for use in standard clinical practice. The utilization of biomarkers to give prescient data, custom-made treatment regimens, and early discovery has significant ramifications for patient thought. This exceptional methodology keeps up with the commitment to endeavouring toward treatment results and patient thriving while likewise working on diagnostic accuracy. The proceeded with study and acknowledgment of biomarkers will without a doubt expect a central part in progressing diagnostic accuracy and, thusly, the overall practicality of medical consideration interventions as we keep on disentangling the intricacies of human diseases.

REFERENCES

1. Amin, M., Tang, S., Shalamanova, L., Taylor, R. L., Wylie, S., Abdullah, B. M., & Whitehead, K. A. (2021). Polyamine biomarkers as indicators of human disease. Biomarkers, 26(2), 77-94.
2. Carlos, A. F., & Josephs, K. A. (2023). The role of clinical assessment in the era of biomarkers. Neurotherapeutics, 20(4), 1001-1018.
3. Chow, S. L., Maisel, A. S., Anand, I., Bozkurt, B., De Boer, R. A., Felker, G. M., ... & Zile, M. R. (2017). Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation, 135(22), e1054-e1091.
4. Condrat, C. E., Thompson, D. C., Barbu, M. G., Bugnar, O. L., Boboc, A., Cretoiu, D., ... & Voinea, S. C. (2020). miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells, 9(2), 276.
5. DeGroat, W., Abdelhalim, H., Patel, K., Mendhe, D., Zeeshan, S., & Ahmed, Z. (2024). Discovering biomarkers associated and predicting cardiovascular disease with high accuracy using a novel nexus of machine learning techniques for precision medicine. Scientific reports, 14(1), 1.
6. Dulewicz, M., Kulczyńska-Przybik, A., Mroczko, P., Kornhuber, J., Lewczuk, P., & Mroczko, B. (2022). Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: The role of CSF biomarkers during the evolution of diagnostic criteria. International Journal of Molecular Sciences, 23(15), 8598.
7. Hajjo, R., Sabbah, D. A., & Al Bawab, A. Q. (2022). Unlocking the potential of the human microbiome for identifying disease diagnostic biomarkers. Diagnostics, 12(7), 1742.
8. Hampel, H., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., ... & Dubois, B. (2014). Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochemical pharmacology, 88(4), 426-449.
9. Hudu, S. A., Alshrari, A. S., Syahida, A., & Sekawi, Z. (2016). Cell culture, technology: enhancing the culture of diagnosing human diseases. Journal of clinical and diagnostic research: JCDR, 10(3), DE01.
10. Kanwal, R., Plaga, A. R., Liu, X., Shukla, G. C., & Gupta, S. (2017). MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Letters, 407, 9-20.
11. Kermali, M., Khalsa, R. K., Pillai, K., Ismail, Z., & Harky, A. (2020). The role of biomarkers in diagnosis of COVID-19–A systematic review. Life sciences, 254, 117788.
12. Marrocco, I., Altieri, F., & Peluso, I. (2017). Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxidative medicine and cellular longevity, 2017.

13. Mischak, H., Delles, C., Vlahou, A., & Vanholder, R. (2015). Proteomic biomarkers in kidney disease: issues in development and implementation. Nature Reviews Nephrology, 11(4), 221-232.
14. Reichl, P., & Mikulits, W. (2016). Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians. Oncology reports, 36(2), 613-625.
15. Rivera-Barahona, A., Pérez, B., Richard, E., & Desviat, L. R. (2017). Role of miRNAs in human disease and inborn errors of metabolism. Journal of inherited metabolic disease, 40(4), 471-480.
16. Rossini, P. M., Di Iorio, R., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M., ... & Dubois, B. (2020). Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. Clinical Neurophysiology, 131(6), 1287-1310.
17. Toader, C., Dobrin, N., Brehar, F. M., Popa, C., Covache-Busuioc, R. A., Glavan, L. A., ... & Ciurea, A. V. (2023). From recognition to remedy: The significance of biomarkers in neurodegenerative disease pathology. International journal of molecular sciences, 24(22), 16119.
18. Wagatsuma, K., Yokoyama, Y., & Nakase, H. (2021). Role of biomarkers in the diagnosis and treatment of inflammatory bowel disease. Life, 11(12), 1375.
19. Yang, W. L., Lu, Z., & Bast Jr, R. C. (2017). The role of biomarkers in the management of epithelial ovarian cancer. Expert review of molecular diagnostics, 17(6), 577-591.
20. Zeng, L., Cui, J., Wu, H., & Lu, Q. (2014). The emerging role of circulating microRNAs as biomarkers in autoimmune diseases. Autoimmunity, 47(7), 419-429.
21. Josphineleela, R., Raja Rao, P. B. V., Shaikh, A., & Sudhakar, K. (2023). A Multi-Stage Faster RCNN-Based iSPLInception for Skin Disease Classification Using Novel Optimization. Journal of Digital Imaging, 1-17.
22. Raja Rao, P. B. V., Prasad, M., Kiran Sree, P., Venkata Ramana, C., & Satyanarayana Murty, P. T. (2022, December). Enhancing the MANET AODV Forecast of a Broken Link with LBP. In International Conference on Intelligent Systems and Sustainable Computing (pp. 51-69). Singapore: Springer Nature Singapore.
23. Pilli, B. V., Nagarajan, S., & Devabalan, P. (2021). Detecting the Vehicle's Number Plate in the Video Using Deep Learning Performance. Review of International Geographical Education Online, 11(5).
24. Raja Rao, P. B. V., & Sharma, N. (2021). Intellectual Routing Mechanism for Improving Qos in Manets for Secure Data Transmission. Turkish Journal of Computer and Mathematics Education (TURCOMAT), 12(6), 4659-4668.